Open label phase 1b/2 study of ladiratuzumab vedotin in combination with   pembrolizumab for first-line treatment of patients with unresectable   locally-advanced or metastatic triple-negative breast cancer

Document type:: Meeting Abstract
Author(s):: Han, Hyo (Heather); Diab, Sami; Alemany, Carlos; Basho, Reva; Brown-Glaberman, Ursa; Meisel, Jane; Pluard, Timothy; Cortes, Javier; Dillon, Patrick; Ettl, Johannes; Kuemmel, Sherko; Sanchez, Luis Manso; Oliveira, Mafalda; O'Shaughnessy, Joyce; Papish, Steven; Sinha, Rajni; Sterrenberg, Danielle; Stringer-Reasor, Erica; Tsai, Michaela; Vazquez, Rafael Villanueva; Wuerstlein, Rachel; Wang, Yinghui; Wang, Zejing; Boni, Valentina
Title:: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Journal title abbreviation:: Cancer Res
Year:: 2020
Journal volume:: 80 Suppl S
Journal issue:: 4
Fulltext / DOI:: doi:10.1158/1538-7445.SABCS19-PD1-06
Print-ISSN:: 0008-5472
TUM Institution:: Frauenklinik und Poliklinik
BibTeX

Occurrences: